Gemcitabine and carboplatin treatment in advanced NSCLC: a retrospective evaluation including elderly patients.

Background: Carboplatin-containing regimens are sometimes preferred for patients with advanced non-small cell lung cancer.

Methods: Eighty-three patients with stage III-IV non-small cell lung cancer received 3 to 4 cycles of carboplatin AUC 5 on day 2 and gemcitabine 1250 mg/m2 on days 1 and 8 every 21 days.

Results: The overall response rate was 43.